Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2019-01-21 Regulatory Filings
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Start av jämförande prövarinitierad studie av ledfunktionen hos Episealer®-patienter
Regulatory Filings Classification · 95% confidence The document is a press release from Episurf Medical announcing the start of a comparative clinical study for their Episealer® implant. It details the study's title, location, purpose, and expected results timeline. The text concludes with standard company information and a statement that the information is being made public under EU Market Abuse Regulation, released on January 21, 2019. This type of announcement, which is a specific operational/clinical update that doesn't fit neatly into financial reports (10-K, IR, ER) or governance documents (DEF 14A, CGR), is best classified as a general Regulatory Filing or Announcement. Since there is no specific category for 'Clinical Trial Announcement' and it is not a formal financial report, the most appropriate fallback is 'Regulatory Filings' (RNS), as it is an official public disclosure required under market rules.
2019-01-21 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage by 'Serendipity Group AB' concerning 'Episurf Medical AB'. It explicitly shows the 'Before the transaction' and 'After the transaction' share quantities and voting rights, and mentions the 'Reason for major shareholding notification Sell'. This structure is characteristic of a notification regarding a change in significant ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is a direct report of the change, not an announcement of a report.
2019-01-17 English
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document explicitly details a change in shareholding ('Reason for major shareholding notification Buy') by a holder (Avanza Bank Holding AB) in the issuer (Episurf Medical AB). It specifies the 'Before the transaction' and 'After the transaction Quantity' of shares and the resulting 'Percentage' of voting rights. This structure perfectly matches the definition of a Major Shareholding Notification, which corresponds to the filing code MRQ.
2019-01-14 English
New US patent approval for Episurf Medical
Legal Proceedings Report Classification · 90% confidence The document announces the receipt of a 'Notice of Allowance' from the USPTO for a new patent related to cartilage repair technology. It includes quotes from the CRO & Head of IP and contact information. This type of announcement, concerning intellectual property rights (patents), does not fit neatly into the primary financial reporting categories (10-K, IR, ER, etc.). While it relates to company assets, it is a specific legal/IP update. Given the available options, 'Legal Proceedings Report (LTR)' is the closest fit as it covers significant legal/regulatory matters, although patents are generally positive. However, since there is no specific 'Intellectual Property Filing' code, and this is a specific announcement about a legal/regulatory outcome (patent approval), 'LTR' is the most appropriate category among the choices, as it deals with official legal/regulatory documentation outcomes. If 'RNS' (Regulatory Filings) were used as a catch-all, it would also apply, but LTR captures the nature of the content (a legal/IP milestone) better than the general RNS.
2018-12-28 English
Nytt patentbeviljande i USA för Episurf Medical
Regulatory Filings Classification · 90% confidence The document announces that the USPTO (US Patent and Trademark Office) intends to grant a new patent to Episurf Medical for a method related to surgical equipment for cartilage injuries. This is a specific announcement regarding intellectual property (IP) and patent rights. Among the provided categories, 'LTR' (Legal Proceedings Report) is the closest fit as patents often fall under legal/IP matters, although 'RNS' (Regulatory Filings) is a general fallback. Given the specific nature of a patent grant announcement, which is a significant legal/IP event, and the lack of a dedicated 'Patent Grant' category, 'LTR' (Legal Proceedings Report) is chosen as it covers significant legal/regulatory matters, or 'RNS' as a general regulatory announcement. Since this is a positive announcement about IP protection rather than a lawsuit or regulatory action, and it is a specific type of corporate update, 'RNS' (Regulatory Filings) serves as the most appropriate general regulatory announcement category when a more specific IP category is absent, as it is a formal public disclosure required under market abuse regulations (mentioned at the end). However, since the content is purely about a patent grant, which is a form of regulatory/legal update, and 'LTR' covers legal proceedings, I will lean towards 'RNS' as the most general fit for non-standard, specific regulatory news, or re-evaluate if 'LTR' is better. Given the options, 'RNS' is the safest catch-all for specific, non-financial, non-management regulatory news. The document explicitly states it is information Episurf Medical AB is obliged to disclose under the EU Market Abuse Regulation, confirming its regulatory nature.
2018-12-28 Swedish
Change in number of shares and votes in Episurf Medical
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly details a 'Change in number of shares and votes' resulting from the conversion of convertible bonds. This action directly impacts the company's capital structure and the total number of outstanding shares. This aligns precisely with the definition of 'Share Issue/Capital Change' (SHA), which covers changes in capital structure, including those resulting from debt conversion into equity. It is not an earnings release (ER), an interim report (IR), or a general regulatory filing (RNS), as it concerns a specific capital event.
2018-12-28 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.